aTyr Pharma reports positive Phase 1b/2a post-hoc data for efzofitimod in sarcoidosis

aTYR PHARMA INC

Therapeutic doses (3.0 & 5.0 mg/kg) reduced steroid relapse rate to 7.7% vs 54.4% (p=0.017).
FVC rate of change significantly improved for therapeutic vs placebo/subtherapeutic group (p=0.035).
52.9% of therapeutic group achieved ≥12 KSQ-L improvement (3x MCID) vs 15.0% (p=0.032).
64.7% of therapeutic group met composite responder endpoint vs 20.0% (p=0.008).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.